帕博利珠单抗联合AP对非小细胞肺癌患者疗效及血清sMICA水平的影响  

EEffect of pembrolizumab combined with AP on efficacy and serum sMICA levels in pa⁃tients with non⁃small cell lung cancer

作　　者：徐红利 李君霞[1] 张佳佳[1] 杨海鹏[1] 陈爽[1] XU Honghong;LI Junxia;ZHANG Jiajia;YANG Haipeng;CHEN Shuang(Department of Pharmacy,Henan Chest Hospital/Affiliated Chest Hospital of Zhengzhou University,Zhengzhou,Henan,China,450000)

机构地区：[1]河南省胸科医院/郑州大学附属胸科医院药剂科,河南郑州450000

出　　处：《分子诊断与治疗杂志》2024年第7期1255-1258,共4页Journal of Molecular Diagnostics and Therapy

基　　金：河南省医学科技攻关计划项目(LHGJ20201238)。

摘　　要：目的 分析帕博利珠单抗联合培美曲塞+顺铂(AP)对非小细胞肺癌(NSCLC)患者疗效及血清可溶性MHC-1类链相关蛋白A(sMICA)水平的影响。方法 根据随机字表法将2019年3月至2022年3月期间河南省胸科医院收治的102例NSCLC患者分为两组,对照组(n=51)采用AP方案;研究组(n=51)采用AP联合帕博利珠单抗;分析两组疗效、血清sMICA水平、生活质量评分、随访1年的生存率和不良反应。结果 研究组缓解率和疾病控制率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清sMICA水平低于治疗前,且研究组血清sMICA水平低于对照组,差异有统计学意义(P<0.05)。研究组生活质量好转率显著高于对照组,差异有统计学意义(P<0.05)。随访期间无失访病例,研究组生存率(44/51)显著高于对照组(35/51),差异有统计学意义(χ^(2)=5.631,P<0.05)。两组不良反应比较差异无统计学意义(P>0.05)。结论 帕博利珠单抗联合培美曲塞+顺铂可以提高NSCLC患者疾病控制率,降低血清sMICA水平。Objective To analyze the effects of pembrolizumab combined with pemetrexed+cispla-tin(AP)on the efficacy and serum soluble MHC-1 chain-associated protein A(sMICA)levels in patients with non-small cell lung cancer(NSCLC).Methods According to the random word table method,102 NSCLC pa-tients admitted to Henan Chest Hospital from March 2019 to March 2022 were divided into two groups.The con-trol group(n=51)received the AP regimen.The research group(n=51)received AP combined with pembroli-zumab.The study analyzed the efficacy,serum sMICA levels,quality of life scores,1-year follow-up survival rate,and adverse reactions of both groups.Results The remission rate and disease control rate of the research group were higher than those of the control group,and the difference was statistically significant(P<0.05).After treatment,the serum sMICA levels in the two groups were lower than before treatment,and the serum sMICA levels in the study group were lower than those in the control group,with a statistically significant differ-ence(P<0.05).The improvement rate of quality of life in the research group was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).There were no missing cases dur-ing the follow-up period.The survival rate of the study group(44/51)was significantly higher than that of the control group(35/51)(χ^(2)=5.631,P<0.05).There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion The pembrolizumab combined with pemetrexed+cisplatin can enhance the disease control rate and reduce serum sMICA levels in NSCLC patients.

关 键 词：帕博利珠单抗 培美曲塞 顺铂 非小细胞肺癌 可溶性MHC-I类链相关蛋白A 

分 类 号：R734.2[医药卫生—肿瘤]